Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1,001 - 10,000 - Monthly Reach
Unique listeners across all episodes (30 days)
5,001 - 25,000 - Active Followers
Loyal subscribers who consistently listen
501 - 5,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Dirk Foell on trends in paediatric rheumatology care across Europe
Apr 21, 2026
16m 00s
Jon Lampa on patient-reported outcomes from the NORD-STAR trial
Mar 23, 2026
15m 26s
Coziana Ciurtin on long-term outcomes of childhood-onset Sjögren’s disease
Feb 23, 2026
35m 48s
Fiona Pearce and Rachel Tattersall on HLH mortality rates in Europe
Jan 26, 2026
34m 36s
John Isaacs and Josh Bennett on sarcopenia in rheumatoid arthritis
Dec 15, 2025
19m 25s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/21/26 |  Dirk Foell on trends in paediatric rheumatology care across Europe | In this episode, Professor Dirk Foell from University Hospital Münster unpacks the findings from a recent Europe-wide survey examining trends in paediatric rheumatology care. Despite significant scientific advances, delivering consistent, high-quality care for children with rheumatic and musculoskeletal diseases remains a challenge. Drawing on Professor Foell's recent Viewpoint, we discuss variation in paediatric rheumatology training pathways, subspecialty accreditation, and professional recognition across Europe, and how these disparities can impact workforce development and clinical care. Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00378-9/fulltext | 16m 00s | ||||||
| 3/23/26 | Jon Lampa on patient-reported outcomes from the NORD-STAR trial | As part of The Lancet Rheumatology’s special issue on public and patient involvement in rheumatology, in this month’s episode, Aisling talks to Professor Jon Lampa about his recent publication on the patient-reported outcomes from the NORD-STAR trial. The 2023 NORD-STAR trial was the first randomised trial to compare three different biological DMARDs, all in combination with methotrexate with active conventional treatment in patients with early rheumatoid arthritis. The study showed that aft... | 15m 26s | ||||||
| 2/23/26 | Coziana Ciurtin on long-term outcomes of childhood-onset Sjögren’s disease | In this month’s episode we discuss childhood-onset Sjögren’s disease-a rare and under-researched rheumatic condition. Lack of robust clinical and immunological characterisation of this condition alongside assessment of its impact on quality of life has significantly hampered progress in the delivery of high-quality research and evidence-based recommendations for care. There are currently no studies following up children and young people with childhood-onset Sjögren's disease as t... | 35m 48s | ||||||
| 1/26/26 | Fiona Pearce and Rachel Tattersall on HLH mortality rates in Europe | This months episode covers Hemophagocytic lymphohistiocytosis, or HLH, a rare, life-threatening disorder characterised by dysregulated immune activity resulting in systemic inflammation, tissue damage and multiorgan failure which affects both children and adults. The annual prevalence of HLH in England is around 2 per million people in the adult population, with an overall 1-year survival rate of around 50% and similar rates have also been reported in other countries across the world. However... | 34m 36s | ||||||
| 12/15/25 | John Isaacs and Josh Bennett on sarcopenia in rheumatoid arthritis | During this episode, Dr John Isaacs and Dr Josh Bennett from Newcastle University and the NIHR Newcastle Biomedical Research Centre, discuss sarcopenia - an age-related loss of muscle mass and strength. Sarcopenia is relatively common in rheumatoid arthritis, with a prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used. Rheumatoid sarcopenia increases the risk of fall, fractures, disability, and hospitalisation. Therefore, prev... | 19m 25s | ||||||
| 11/17/25 | Dr Samuel Bitoun on machine learning to classify the focus score and Sjögren’s disease | This month's episode covers Sjögren’s disease—an autoimmune condition that primarily affects areas of the body that produce fluids, such as tears and saliva. The cause of the disease isn’t understood. Currently there are no licensed drugs to treat the disease, but phase 2 clinical trials have reported encouraging results, and phase 3 trials are underway. Dr Samuel Bitoun, from the University of Paris-Saclay and APHP, discusses how Sjögren’s disease is currently classified, the challenges of ... | 11m 12s | ||||||
| 10/20/25 | Ryan Hum on synovial immunopathology in psoriatic arthritis | In today's episode, Sophie discusses psoriatic arthritis with Dr Ryan Hum from The University of Manchester. Psoriatic arthritis affects between 0.1% and 1% of the general population globally, and appears to be more prevalent in certain regions. It affects men and women equally and typically appears between the ages of 30 and 55 years. Psoriatic arthritis tends to be more common in people with psoriasis affecting around 20% of individuals, but estimates can depend on the inclusion criteria s... | 26m 48s | ||||||
| 9/22/25 | Scott Uhlrich on personalised gait retraining for knee osteoarthritis | In this episode, we’re tackling a condition that affects over 374 million people worldwide—knee osteoarthritis (OA). As the most common site of OA, knee OA is a leading cause of disability and accounts for more than 12 million disability-adjusted life years globally. With prevalence rising steadily due to aging populations and increasing obesity rates, the burden of knee OA is projected to climb even further in the coming decades. We speak with the lead author of a new study published in The... | 16m 26s | ||||||
| 8/18/25 | Mark Hancock on low back pain | In this episode, we'll be discussing an issue that affects millions of people globally - low back pain. We will find out why the burden of low back pain is so high, why current management is so ineffective, what we can do from a research and care perspective to improve outcomes for patients, and whether prevention is the way forward. We’ll also discuss a couple of papers that have been recently published in The Lancet Rheumatology looking at longer-term treatment options for low back pa... | 10m 20s | ||||||
| 7/21/25 | Vibeke Strand on polymyalgia rheumatica | In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not respond to treatment. We also cover her recent publication, which explores the patient reported out... | 11m 32s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/20/25 | Xue Li on access to biologics in the Asia-Pacific region | This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability. In this episode, we explore the factors that may have delayed the popularisation of biologics in Asia, any recent p... | 19m 31s | ||||||
| 6/16/25 | Sinisa Savic on treatment outcomes in VEXAS syndrome | In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research. VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene,... | 12m 07s | ||||||
| 6/3/25 | Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy | This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions. Read the full article: https://www.thelancet.com/journals/l... | 20m 50s | ||||||
| 4/25/25 | Dominique Farge on allogeneic umbilical cord-derived mesenchymal stromal cells for systemic lupus erythematosus | This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE). We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the futur... | 26m 05s | ||||||
| 3/24/25 | Rebecca Marsh and Grant Schulert on allogeneic HSCT for children with refractory sJIA and associated lung disease | The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... | 18m 30s | ||||||
| 2/24/25 | Bryant England on advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease | Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://insta... | 8m 30s | ||||||
| 1/27/25 | Brooke Conley and Ivan Lin on the development of arthritis educational resources for Aboriginal and Torres Strait Islander peoples in Australia | Dr Brooke Conley and Associate Professor Ivan Lin discuss their recent study on integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv | 18m 30s | ||||||
| 12/23/24 | Mark Russell and Sherry Yang on the inequities in rheumatological care in the UK and USA | Dr Mark Russell and Sherry Yang discuss the factors influencing initiation of biologics in underserved populations with rheumatoid arthritis in the UK, how historical redlining and present-day racialised economic segregation affects health-care utilisation of adults with rheumatic diseases in the USA, and health inequities seen in rheumatology more broadly. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00221-2/fulltext?dgcid=buzzsprout_icw_podcast_... | 25m 28s | ||||||
| 11/25/24 | Quirine Dumoulin on the 4-year data from the TREAT-EARLIER trial | Dr Quirine Dumoulin discusses the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00196-6?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelanc... | 15m 38s | ||||||
| 10/21/24 | Sebastian Sattui on older adults with ANCA-associated vasculitis | Dr Sebastian Sattui discusses the effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00193-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup ... | 25m 54s | ||||||
| 9/23/24 | Celebrating 5 years of The Lancet Rheumatology with Oliver Distler, Laura Coates, and David Liew | To celebrate 5 years of The Lancet Rheumatology, international advisory board members Oliver Distler, Laura Coates, and David Liew discuss recent progress made, challenges to overcome, and future directions in rheumatology. Read the associated Editorial: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00245-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/... | 58m 02s | ||||||
| 7/22/24 | Karen Schreiber, Ian Giles, and Angela Tincani on the Pregnancy and Rheumatic Diseases Series | Dr Karen Schreiber, Professor Ian Giles, and Professor Angela Tincani discuss the Series on Pregnancy and Rheumatic Diseases, including the use of DMARDs during pregnancy, study design and conduct, and outcomes for children born to mothers with rheumatic diseases. Read the Series: https://thelancet.com/series/pregnancy-rheumatic-diseases?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com... | 34m 33s | ||||||
| 6/17/24 | Dr Maria Tektonidou on cardiovascular risk factors in systemic lupus erythematosus | Dr Maria Tektonidou discusses the results of a cross-sectional analysis of international data on cardiovascular risk factors in systemic lupus erythematosus. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv | 11m 20s | ||||||
| 5/21/24 | Rosemary Hollick on improving services for adults with rare autoimmune rheumatic diseases | Dr Rosemary Hollick, University of Aberdeen, discusses a mixed-methods study on key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv | 16m 17s | ||||||
| 1/18/23 | Clinical Realities: Heather Van Epps, Anna Clark, Lola Falasinnu, David Liew, and Puja Mehta | Editors Heather Van Epps and Anna Clark join guest hosts Lola Falasinnu, David Liew, and Puja Mehta to reflect on the progress of The Lancet Rheumatology and share their vision for the future. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv | 25m 35s | ||||||
Showing 25 of 35
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
4 placements across 4 markets.
Chart Positions
4 placements across 4 markets.